Startups
Acepodia is a clinical stage biotech company dedicated to the development of targeted, allogeneic, off-the-shelf cell therapies to eradicate cancers.
Antibody-Cell Conjugation (ACC) platform, its novel technology links tumor-targeting antibodies to the surface proteins of its proprietary immune cells, oNK and γδ T cells. No complicated genetic engineering is required; therefore, the conjugation technology could be powerful, versatile, affordable and safe. The Antibody-Conjugated Effector (ACE) cells significantly increases the avidity with cancer cells, which activates immune system and leads to effectively identifying and eliminating the targeted cancer cells robustly.
Our vision is to develop an off-the shelf cell therapy that is potent, safe and broadly applicable across hematologic and solid tumor cancers. Our lead product candidate, ACE1702, is an anti-HER2 antibody-conjugated NK cell therapy entering in Phase I trial at U.S. for the treatment of HER2-expressing solid tumors. The second program, ACE1831, is an anti-CD20-antibody-conjugated γδ T cell therapy being on track for IND filing to the US FDA in the second half of 2021.
Antibody-Cell Conjugation (ACC) platform, its novel technology links tumor-targeting antibodies to the surface proteins of its proprietary immune cells, oNK and γδ T cells. No complicated genetic engineering is required; therefore, the conjugation technology could be powerful, versatile, affordable and safe. The Antibody-Conjugated Effector (ACE) cells significantly increases the avidity with cancer cells, which activates immune system and leads to effectively identifying and eliminating the targeted cancer cells robustly.
Our vision is to develop an off-the shelf cell therapy that is potent, safe and broadly applicable across hematologic and solid tumor cancers. Our lead product candidate, ACE1702, is an anti-HER2 antibody-conjugated NK cell therapy entering in Phase I trial at U.S. for the treatment of HER2-expressing solid tumors. The second program, ACE1831, is an anti-CD20-antibody-conjugated γδ T cell therapy being on track for IND filing to the US FDA in the second half of 2021.
Overview
Location
United States, California, Alameda
Employees
11-50
Total raised
$100M
Founded date
2016
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 21, 2025 | Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025 | ALAMEDA, Calif. and TAIPEI, April 21, 2025 /PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (H... |
| Nov 15, 2024 | Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease | IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Ho... |
| Sep 4, 2024 | Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases | Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases Pfizer Ignite will also provide strategic advisory ... |
| Feb 5, 2024 | Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy | ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 5, 2024 /... |
| Sep 18, 2023 | Acepodia Announces Nobel Laureate Carolyn Bertozzi, Ph.D., as Chief Scientific Advisor | ALAMEDA, Calif. and TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 T-cell platfor... |
| Jun 6, 2023 | Acepodia Secures $100 Million Series D Financing to Advance | First-In-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform Series D led by Digital Mobile Venture with participation from additional existing investors Funds will support expansion and progress of oncology pipeline, includi... |
| Dec 8, 2021 | There are more private equity exits than there have been in 2 decades. How long will it last? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It’s a great time to get out. Paid Content How to build a better future for diverse entrepreneurs... |
| Dec 8, 2021 | There are more private equity exits than there have been in 2 decades. How long will it last? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It’s a great time to get out. Paid Content Optimizing Kubernetes for business security, scalabili... |
| Dec 2, 2021 | Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies | ALAMEDA, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care,... |
Show more
Reviews 0
FAQ about Acepodia
When was Acepodia founded?
Acepodia was founded in 2016.
How much funding has Acepodia raised?
Acepodia has raised $100M in total across 1 funding round.
What has the press written about Acepodia?
Parsers VC has collected 11 articles mentioning Acepodia, among them “Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025” (Apr 21, 2025) and “Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease” (Nov 15, 2024).
Is Acepodia still active?
Yes, Acepodia is active; its latest activity on Parsers VC dates from Sep 4, 2026.